Thu, Nov 21, 2024
Volume 10, Issue 1 (6-2023)
vacres 2023, 10(1): 39-44 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rahpeyma M, Khosravy M S. Rabies vaccine: progress and prospective. vacres 2023; 10 (1) :39-44
URL: http://vacres.pasteur.ac.ir/article-1-339-en.html
URL: http://vacres.pasteur.ac.ir/article-1-339-en.html
Rabies National Reference laboratories & WHO collaborative centers, Department of Virology, Pasteur Institute of Iran, Tehran, Iran.
Abstract: (653 Views)
Rabies is a zoonotic disease, endemic mostly in Asia and Africa. Rabies virus belongs to the family Rhabdoviridae, genus Lyssavirus. Because infection with rabies virus has no cure and is life-threatening, vaccination is an important preventive measure to combat this disease in humans and animals. On the other hand, considering the limited availability of rabies vaccines in some of less developed countries with a higher rate of human rabies death each year, the need for an alternative strategy to produce a cost-effective and immunogenic vaccine against this disease is essential. In this review, we provide a brief overview of rabies vaccine development and its recent basic research. We also describe how viral vectors such as poxvirus vector, adenovirus replicons, and reverse genetics are manipulated for efficient novel formulated vaccines against this infection and we highlight possible future developments
Type of Study: Review article |
Subject:
Vaccine development, efficacy and safety evaluation
Received: 2024/03/12
Received: 2024/03/12
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.